InvestorRelations-1

ACP-01 is an immortal development in the realm of medication

Long
OTC:HMTXF   Hemostemix Inc


The company’s lead candidate for phase II clinical-stage trial is doing wonders in medication, helping patients experiencing ulcers and CLI or other ischemic issues like peripheral artery disease and keeping the patients from getting their limb amputated.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.